drugset / Trial / NCT02793817
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Loteprednol Etabonate | Other / unclassified | 1 % | Other |
Indications
No indication recorded.